Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Instock who wrote (13760)	2/7/1999 8:29:00 PM
From: MoneyMade	Respond to of 29382

BLSI---what do you think?? Boston Life Says Molecule May Halt Tumors BOSTON (Reuters) - Boston Life Sciences Inc (Nasdaq:BLSI - news) said Friday its researches inadvertently identified a molecule in the human body that could be used to prevent the growth of tumors in cancer patients. While preparing another protein, Troponin, for human testing to treat tumor growth and eye diseases, the researchers said they identified another protein that may be even more powerful. ''We identified a second molecule that looks even better than Troponin,'' Dr. Marc Lanser, founder and chief scientific officer of Boston Life Sciences, told Reuters. Troponin is scheduled to begin human testing within five months, Lanser said. Troponin and the as-yet-unnamed second molecule are both anti-angiogenic agents that could prevent tumors from growing by cutting off their blood supply. The process is important, Lanser said, because many cancer patients end up dying from metastatic tumors, or metastases. Metastases are secondary tumors, related to the first, that attack the body long after the initial cancer has been removed. For example, a colon cancer removed from a patient can reappear and kill the patient five years later when it returns in the form of metastases that have grown throughout the body. ''It's a potentially non-toxic approach to the treatment of all tumor growth,'' Lanser said. Both molecules occur naturally in the body, but are not plentiful enough to suffocate the tumors on their own. Lanser said the molecule identified earlier this week could be ready for human testing within a year if clinical tests confirm it may be more potent than Troponin or that it could work in conjunction with Troponin. The company next step is for the company to seek a patent, make more of the molecules and conduct animal testing. ''We're very encouraged,'' Lanser said. Boston Life's stock was up 1/16 at 5, in early afternoon trading. For related news, double click on one of the following codes: E U DRU US SCI LEN RTRS BLSI.Oc For related price quotes, double click on one of the following codes: Friday, 5 February 1999 17:44:24 RTRS nN05159245